1.55  0.01 (0.65%)		04-17 16:00
Open: 1.56 High: 1.59 Volume: 36,734		Pre. Close: 1.54 Low: 1.5101 Market Cap: 46(M)

Short term
Mid term
Targets	6-month :	2.03	1-year :	2.27
Resists	First :	1.73	Second :	1.95
Pivot price	1.52
Supports	First :	1.39	Second :	1.16
MAs	MA(5) :	1.54	MA(20) :	1.56
	MA(100) :	1.86	MA(250) :	2.6
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	56.7	D(3) :	57
RSI	RSI(14): 46.6
52-week	High :	5.98	Low :	1.39

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ MAIA ] has closed below upper band by 40.3%. Bollinger Bands are 49.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	1.59 - 1.6	1.6 - 1.61
Low:	1.49 - 1.5	1.5 - 1.51
Close:	1.54 - 1.55	1.55 - 1.56

MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.

Tue, 01 Apr 2025
Breakthrough Cancer Drug Pipeline: MAIA's Telomere-Targeting Therapy Eyes FDA Fast Track - Stock Titan

Tue, 01 Apr 2025
MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders - Business Wire

Fri, 28 Mar 2025
Is MAIA Biotechnology, Inc. (MAIA)he Cheapest Stock Insiders Are Buying In March? - Yahoo Finance

Thu, 27 Mar 2025
MAIA Biotechnology, Inc. (MAIA) Upgraded to Buy: Here's What You Should Know - Yahoo Finance

Tue, 25 Mar 2025
Breakthrough Lung Cancer Drug Shows Exceptional Phase 2 Results: Key Biomarker Discovery - Stock Titan

Thu, 20 Mar 2025
MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug - Business Wire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: AMEX
Sector: Healthcare
Industry: Biotechnology
Shares Out	24 (M)
Shares Float	19 (M)
Held by Insiders	16.3 (%)
Held by Institutions	7.4 (%)
Shares Short	633 (K)
Shares Short P.Month	777 (K)

EPS	-1.63
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.12
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-107.2 %
Return on Equity (ttm)	-559.6 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-15 (M)
Levered Free Cash Flow	-9 (M)

PE Ratio	-0.96
PEG Ratio	0
Price to Book value	11.92
Price to Sales	0
Price to Cash Flow	-2.41

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.